[目的]观察培美曲塞（pemetrexed, PEM）单药一线治疗老年晚期肺腺癌的疗效及毒性反应。[方法]经细胞学或组织学确诊的48例老年晚期肺腺癌非小细胞肺癌（non smal cel lung cancer，NSCLC）患者，均接受单药PEM化疗，培美曲塞二钠以500 mg/m2，第1d静脉滴注，21d为1周期，每例患者至少行2周期化疗；观察临床有效率(RR)、疾病控制率、疾病进展时间（TTP）、生活质量及化疗相关毒副反应。[结果] CR 1例，PR 20例， SD 15例，PD 12例，RR43.8%，临床获益率(CBR)75.0%，平均疾病进展时间TTP 11.2月；生活质量改善50%，稳定33.3%，有效率达83.3%；化疗相关毒副反应较轻，主要为血液学毒性（骨髓抑制）和消化道反应，多为Ⅰ~Ⅱ级，无Ⅳ度毒副反应发生。[结论]单药PEM一线治疗老年晚期肺腺癌具有较好的疗效，而毒性反应较轻。%[Objective] To observe the efficacy and toxicity of pemetrexed alone as first-line drug in the treatment of the elderly patients with advanced lung adenocarcinoma.[Methods]48 elderly patients with advanced lung adenocarcinoma confirmed by pathology or cytology were treated with pemetrexed 500 mg/m2 through intravenous drip.3 weeks was a cycle and each patient was given at least 2 cycles of chemotherapy.[Results]There was only 1 case of complete remission(CR),20 cases of partial remission(PR),15 cases of stable disease(SD) and 12 cases of progressive disease(PD) after the treatment .The overal response rate was 43.8% and the clinical beneficial rate was 75.0%.The median time to progress(TTP) was 11.2 months. The improving of QOL was remarkable. The major adverse reactions were myelosuppression and gastrointestinal reactions .There was no chemotherapy-related death occurred. [Conclusion] Pemetrexed alone in the treatment of elderly patients with advanced lung adenocarcinoma has a better efficacy with lower toxicity and good tolerance.
展开▼
